Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
Byoung Chul Cho, MD, PhD
Advertisement
Articles by Byoung Chul Cho, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Poorer Outcomes Observed for Black Patients Undergoing Chemotherapy for AML
2
All-Oral Revumenib Regimen May Show Advantage in Newly Diagnosed AML
3
Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma
4
Blinatumomab/Ponatinib Provides Chemo-Free Option in Ph+ ALL
5
